1、 MCGEE E U,SAMUEL E,BORONEA B,et al.Quinolone allergy[J].Pharmacy,2019,7(3):97. MCGEE E U,SAMUEL E,BORONEA B,et al.Quinolone allergy[J].Pharmacy,2019,7(3):97.
2、 üNAL D,DEMIR S,GELINCIK A,et al.Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity[J].J Allergy Clin Immunol Pract,2018,6(2):521-527. üNAL D,DEMIR S,GELINCIK A,et al.Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity[J].J Allergy Clin Immunol Pract,2018,6(2):521-527.
3、 BéROT V,GENER G,INGEN-HOUSZ-ORO S,et al.Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction:Experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions[J].J Eur Acad Dermatol Venereol,2020,34(4):787-794. BéROT V,GENER G,INGEN-HOUSZ-ORO S,et al.Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction:Experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions[J].J Eur Acad Dermatol Venereol,2020,34(4):787-794.
4、 ROMANO A,GAETA F,VALLUZZI R L,et al.IgE-mediated hypersensitivity to cephalosporins:Cross-reactivity and tolerability of penicillins,monobactams,and carbapenems[J].J Allergy Clin Immunol,2010,126(5):994-999. ROMANO A,GAETA F,VALLUZZI R L,et al.IgE-mediated hypersensitivity to cephalosporins:Cross-reactivity and tolerability of penicillins,monobactams,and carbapenems[J].J Allergy Clin Immunol,2010,126(5):994-999.
5、 KHAN D A,BANERJI A,BERNSTEIN J A,et al.Cephalosporin allergy:Current understanding and future challenges[J].J Allergy Clin Immunol Pract,2019,7(7):2105-2114. KHAN D A,BANERJI A,BERNSTEIN J A,et al.Cephalosporin allergy:Current understanding and future challenges[J].J Allergy Clin Immunol Pract,2019,7(7):2105-2114.
6、 ESER SIMSEK I,TUBA COGURLU M,AYDOGAN M.Suspected reaction with cephalosporin may be a predictive factor for β-lactam allergy in children[J].Int Arch Allergy Immunol,2019,178(3):248-254. ESER SIMSEK I,TUBA COGURLU M,AYDOGAN M.Suspected reaction with cephalosporin may be a predictive factor for β-lactam allergy in children[J].Int Arch Allergy Immunol,2019,178(3):248-254.
7、 ZAGURSKY R J,PICHICHERO M E.Cross-reactivity in β-lactam allergy[J].J Allergy Clin Immunol Pract,2018,6(1):72-81.e1. ZAGURSKY R J,PICHICHERO M E.Cross-reactivity in β-lactam allergy[J].J Allergy Clin Immunol Pract,2018,6(1):72-81.e1.
8、 TRUBIANO J A,STONE C A,GRAYSON M L,et al.The 3 Cs of antibiotic allergy—classification,cross-reactivity,and collaboration[J].J Allergy Clin Immunol Pract,2017,5(6):1532-1542. TRUBIANO J A,STONE C A,GRAYSON M L,et al.The 3 Cs of antibiotic allergy—classification,cross-reactivity,and collaboration[J].J Allergy Clin Immunol Pract,2017,5(6):1532-1542.
9、 WURPTS G,ABERER W,DICKEL H,et al.Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics:Guideline of the German Society for Allergology and Clinical Immunology(DGAKI)in collaboration with the German Society of Allergology(AeDA),German Society for Pediatric Allergology and Environmental Medicine(GPA),the German Contact Dermatitis Research Group(DKG),the Austrian Society for Allergology and Immunology(?GAI),and the Paul-Ehrlich Society for Chemotherapy(PEG)[J].Allergol Select,2020(4):11-43. WURPTS G,ABERER W,DICKEL H,et al.Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics:Guideline of the German Society for Allergology and Clinical Immunology(DGAKI)in collaboration with the German Society of Allergology(AeDA),German Society for Pediatric Allergology and Environmental Medicine(GPA),the German Contact Dermatitis Research Group(DKG),the Austrian Society for Allergology and Immunology(?GAI),and the Paul-Ehrlich Society for Chemotherapy(PEG)[J].Allergol Select,2020(4):11-43.
10、 TRUBIANO J A,VOGRIN S,CHUA K Y L,et al.Development and validation of a penicillin allergy clinical decision rule[J].JAMA Intern Med,2020,180(5):745-752. TRUBIANO J A,VOGRIN S,CHUA K Y L,et al.Development and validation of a penicillin allergy clinical decision rule[J].JAMA Intern Med,2020,180(5):745-752.
11、 JEIMY S,BEN-SHOSHAN M,ABRAMS E M,et al.Practical guide for evaluation and management of beta-lactam allergy:Position statement from the Canadian Society of Allergy and Clinical Immunology[J].Allergy Asthma Clin Immunol,2020,16(1):95. JEIMY S,BEN-SHOSHAN M,ABRAMS E M,et al.Practical guide for evaluation and management of beta-lactam allergy:Position statement from the Canadian Society of Allergy and Clinical Immunology[J].Allergy Asthma Clin Immunol,2020,16(1):95.
12、 ARIKOGLU T,ASLAN G,BATMAZ S B,et al.Diagnostic evaluation and risk factors for drug allergies in children:From clinical history to skin and challenge tests[J].Int J Clin Pharm,2015,37(4):583-591. ARIKOGLU T,ASLAN G,BATMAZ S B,et al.Diagnostic evaluation and risk factors for drug allergies in children:From clinical history to skin and challenge tests[J].Int J Clin Pharm,2015,37(4):583-591.
13、 JIMENEZ-RODRIGUEZ T W,BLANCA-LOPEZ N,RUANO-ZARAGOZA M,et al.Allergological study of 565 elderly patients previously labeled as allergic to penicillins[J].J Asthma Allergy,2019(12):421-435. JIMENEZ-RODRIGUEZ T W,BLANCA-LOPEZ N,RUANO-ZARAGOZA M,et al.Allergological study of 565 elderly patients previously labeled as allergic to penicillins[J].J Asthma Allergy,2019(12):421-435.
14、 CHIRIAC A M,WANG Y,SCHRIJVERS R,et al.Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database[J].J Allergy Clin Immunol Pract,2018,6(1):139-148.e2. CHIRIAC A M,WANG Y,SCHRIJVERS R,et al.Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database[J].J Allergy Clin Immunol Pract,2018,6(1):139-148.e2.
15、 DESBIENS M,SCALIA P,RAVIKUMAR S,et al.A closer look at penicillin allergy history:Systematic review and meta-analysis of tolerance to drug challenge[J].Am J Med,2020,133(4):452-462.e4. DESBIENS M,SCALIA P,RAVIKUMAR S,et al.A closer look at penicillin allergy history:Systematic review and meta-analysis of tolerance to drug challenge[J].Am J Med,2020,133(4):452-462.e4.
